Q-omics provides the consensus-scored TAF6L profile across patient tissues and cancer cell-line models. TAF6L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TAF6L is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, TAF6L protein abundance shows 23,914 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where TAF6L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF6L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF6L survival associations across molecular data types. TAF6L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF6L RNA expression–survival associations across cancer types. High TAF6L expression shows unfavorable associations in ACC, LGG and KICH, but favorable associations in SCLC, HNSC and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TAF6L RNA expression.
This table summarizes TAF6L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TAF6L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF6L shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, COAD, HNSC and LIHC. The BLCA box plot shows higher TAF6L RNA expression in tumor versus normal tissue (log2 FC = +0.719, t-test p < 0.001).
This table shows molecular features associated with TAF6L in patient tissues and cancer cell lines. In patient samples, TAF6L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF6L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
